This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Fully published results from Athos Therapeutics AZALEA-TIMI 71 trial for its novel Factor XI inhibitor abelacimab, confirming the drugs lower bleeding risks, but leaving researchers uncertain about its ability to prevent stroke in AFib patients. vs. 0.4%) and 4X ischemic stroke rates (csHR = 4.06). year follow-up. per 100 person-year.
These included three cases of intraoperative thrombosis, three instances of pericardial effusion or tamponade, one case of device-related thrombosis, one peri-device leak, one systemic embolism, one bleeding episode, and one additional device-related complication.
Stroke, Volume 55, Issue 2 , Page 311-323, February 1, 2024. Intracranial atherosclerotic disease (ICAD) is one of the most common causes of stroke worldwide. In addition to stroke, ICAD increases the risk of dementia and cognitive decline, magnifying ICAD societal burden.
A 42-year-old female with SLE, lupus cerebritis with related seizure disorder, and mesenteric venous thrombosis on warfarin initially presented for syncope. Acute stroke workup was negative, and syncope was attributed to possible brief seizure. Circulation, Volume 150, Issue Suppl_1 , Page A4145271-A4145271, November 12, 2024.
Left atrial appendage (LAA) thrombus is the primary cause of stroke and systemic embolism in atrial fibrillation (AF). Novel oral anticoagulants (NOACs) effectively reduce the prevalence of LAA thrombosis and stroke risk.
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. 3 The third‐generation iteration of the Pipeline Embolization Device (PED) incorporates Shield technology, a phosphorylcholine coating designed to reduce thrombogenicity via mimicry of native cell membranes.4
Stroke, Volume 55, Issue Suppl_1 , Page A134-A134, February 1, 2024. In severe OHSS, increases in capillary permeability can result in hemoconcentration and hypercoagulability leading to thrombotic events, including stroke and cerebral venous thrombosis. There were 1,955 hospitalizations for OHSS in NIS.
Stroke, Volume 55, Issue Suppl_1 , Page A139-A139, February 1, 2024. Background:A current national priority is to understand geographic disparities in mechanical thrombectomy (MT) provision for patients with acute ischemic stroke (AIS).
to 11.0)), stroke (3.5 (1.2 to 10)), pulmonary embolism (24.6 to 44.9)) and deep venous thrombosis (7.8 (4.3 to 4.9)) and stroke (2.6 (95% COVID-19 likely increases relative risk (RR (95% CI)) of myocardial infarction (3.3 (1.0 Other RTIs also likely increase the RR of myocardial infarction (2.9 (95% 95% CI 1.8
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. IntroductionCerebral venous sinus thrombosis (CVST) presents diagnostic challenges, especially in its overlap with idiopathic intracranial hypertension (IIH). A cerebral angiogram showed a left occipital AV fistula, treated with onyx embolization.
The primary efficacy and safety end points were stroke or systemic embolism and major bleeding (International Society on Thrombosis and Hemostasis definition), respectively. The stroke or systemic embolism rate was lower with edoxaban than placebo in both weight groups (≤45 kg: hazard ratio [HR], 0.36 [95% CI, 0.16–0.80];
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. IntroductionThe use of detachable coils for endovascular embolization of cerebral aneurysms has become a safe and effective alternative to direct surgical clipping in patients with ruptured aneurysmal subarachnoid hemorrhage.
Stroke, Volume 56, Issue Suppl_1 , Page AWP328-AWP328, February 1, 2025. Migraine with aura(MwA) is associated with an increased risk of stroke and adverse vascular outcomes compared to those with migraine without aura (MwoA). Patients with any adverse vascular outcomes before the index ECG were excluded.
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. SAH severity was determined using the National Institute of Health Stroke Scale as a template. Both anticoagulants can be used intraoperatively and postoperatively for DVT prophylaxis in patients undergoing subarachnoid hemorrhage (SAH) treatment.
Stroke, Volume 56, Issue Suppl_1 , Page ATMP43-ATMP43, February 1, 2025. Background:Disparities in anticoagulation therapy, driven by race, age, and insurance status, affect access to direct oral anticoagulants (DOACs). Patients were drawn from neurology, cardiology, and other services.
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. IntroductionSubarachnoid Hemorrhage (SAH) resulting from the spontaneous rupture of an aneurysm is a rare and highly debilitating condition.
Stroke-volume:50 ml. MINOCA may be due to: coronary spasm, coronary microvascular dysfunction, plaque disruption, spontaneous coronary thrombosis/emboli , and coronary dissection; myocardial disorders, including myocarditis, takotsubo cardiomyopathy, and other cardiomyopathies. Left ventricular end-diastolic volume: 99 ml.
Stroke, Volume 55, Issue Suppl_1 , Page ATP225-ATP225, February 1, 2024. Background and Purpose:Cancer increases the risk for acute ischemic stroke (AIS) and deep venous thrombosis. The role of paradoxical embolization as a stroke etiology in patients with cancer is uncertain.
Stroke, Volume 55, Issue Suppl_1 , Page AWMP49-AWMP49, February 1, 2024. Introduction:COVID-19 infection has thus emerged to be a new risk factor for Cerebral Venous Thrombosis (CVT). CVT with COVID patients were more likely to develop deep vein thrombosis at one month (19.8% All-cause mortality was the primary outcome.
stroke), peripheral arterial disease, congenital heart anomalies, deep vein thrombosis, and pulmonary embolism. Cardiovascular diseases (CVDs) encompass a range of disorders affecting the heart and blood vessels, such as coronary heart disease, cerebrovascular disease (e.g.,
However, after the procedure, moderate pericardial effusion developed in one patient (0.7%) and an acute pulmonary embolism related to femoral vein thrombosis was observed in one patient (0.7%) during the first month. All of the patients had a >10 mm long-tunnel PFO.ResultsThe procedural success rate was 100%.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content